Back to news
AnalysisMay 20, 2026· 3 min read

Women with Parkinson's face higher fall and pain rates than men, study finds

Australian research of 11,000 Parkinson's patients reveals sex-based differences in disease progression. Women report more falls and pain; men show higher cognitive decline and pesticide exposure.

Our Take

Sex-based differences in Parkinson's presentation are real and measurable, but the study does not explain causation—only that clinical patterns diverge, demanding stratified rather than one-size-fits-all care protocols.

Why it matters

Parkinson's diagnostics and treatment protocols have historically been developed without accounting for sex-based variation. This data forces clinicians and researchers to acknowledge that disease progression follows different trajectories by sex, which changes how patients are monitored and treated.

Do this week

Neurologists: audit your current Parkinson's screening and monitoring checklists for sex-blind assumptions—particularly around fall risk, pain assessment, and cognitive testing—and flag gaps before your next patient intake review.

Women and men with Parkinson's show distinct symptom patterns

Researchers at QIMR Berghofer Medical Research Institute analyzed data from nearly 11,000 Australian Parkinson's patients, identifying substantial sex-based differences in how the disease manifests and progresses. The findings were published in The Lancet Regional Health Western Pacific.

Women reported higher rates of falls (45% versus 41% in men), pain (70% versus 63%), depression, and anxiety. They were also more likely to experience one-sided symptom onset (81% versus 75%). Men, by contrast, showed higher rates of memory changes (67% versus 61%) and cognitive impairment. Men also reported more REM-sleep behaviour disorder and sleep apnoea compared to women, and higher rates of impulsive sexual behaviour (56% versus 19%).

Environmental exposure patterns differed markedly. Men reported significantly higher pesticide exposure (42% versus 28%) and were far more likely to have worked in high-risk occupations including farming, metal work, and petrochemicals (44% versus 16%). Overall, 36% of the cohort reported pesticide exposure, and 16% reported a history of traumatic head injury.

Miguel Rentería, the study's lead author, noted: "Parkinson's is not a one-size-fits-all disease. The distinct patterns we see in men and women may reflect different underlying biological pathways and environmental exposures."

Clinical care has ignored sex-based variation for decades

Current Parkinson's clinical guidelines are built on aggregate data that obscure these sex-based differences. A 45% fall rate in women versus 41% in men may look modest in population averages, but the gap signals distinct biomechanical or neurological vulnerabilities that demand different prevention strategies, monitoring cadences, and therapeutic targets.

The same applies to pain management, depression screening, and cognitive assessment. If men are more prone to memory loss and women to motor instability, treatment prioritization—physical therapy intensity, cognitive screening frequency, pharmacological choices—should differ. The data does not prove causation (pesticide exposure in men may or may not directly cause Parkinson's, as the researchers acknowledge), but it establishes that risk factors and symptom severity cluster differently by sex.

This is especially urgent because Parkinson's diagnosis often lags in women, partly because early symptoms present differently and screening tools may be calibrated to male presentation patterns.

What clinicians should do now

Neurologists and geriatricians should immediately audit fall-risk protocols for women (static scores may underestimate actual risk) and cognitive screening tools for men. Pain assessment and mood screening in women should move higher in the diagnostic hierarchy, not lower. Occupational and environmental history taking should include detailed pesticide and chemical exposure, particularly for male patients with recent-onset Parkinson's.

Researchers designing new Parkinson's trials and registries should stratify by sex from the outset, not post-hoc. Pharmaceutical companies developing symptom-management drugs should ensure phase trials include sufficient female enrollment to detect sex-specific efficacy or tolerability signals.

Primary care physicians should recognize that a woman presenting with recent-onset pain and gait instability may have early Parkinson's even without prominent tremor; the same holds for men with early memory loss, which may be misattributed to normal aging.

#Healthcare AI#Research#AI Ethics
Share:
Keep reading

Related stories